Gabapentin Versus Estrogen for the Treatment of Hot Flashes

Phase 4 Completed 60 enrolled University of Rochester Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) · collab National Institutes of Health (NIH) · collab

RandomizedParallel-groupDouble-blindTreatment

Summary

To compare the efficacy and safety of gabapentin, estrogen and placebo in the treatment of hot flashes and other climacteric symptoms.

Timeline

Start: 2002-05
Primary completion: —
Completion: 2004-09

Outcome

Met primary endpoint

paper reduction in the hot flush composite score for both estrogen (72%, P = .016) and gabapentin (71%, P = .004) was greater than the reduction associated with placebo (54%) PMID 16816054 ↗

Publications

Results Reddy SY, Warner H, Guttuso T Jr, Messing S, DiGrazio W, Thornburg L, Guzick DS. Gabapentin, estrogen, and placebo for treating hot flushes: a randomized controlled trial. Obstet Gynecol. 2006 Jul;108(1):41-8. doi: 10.1097/01.AOG.0000222383.43913.ed.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Gabapentin	Unknown	2400 mg	—
Subject	conjugated estrogens	Other / unclassified	0.625 mg	—

Indications

No indication recorded.